

Collaborative Working Project Executive Summary

Project title	Wessex AHSN Lipid Pathway Mapping Project
Partner organisation/s	Wessex AHSN Sanofi
Project rationale	<p>The overall aim of Wessex AHSN working in partnership with Sanofi is to understand the different lipid pathways within the region, identifying the existing pressure points within services and whether inequity exists in this clinical area that contributes to overall health inequalities. The hope is that better understanding of these services and how they are meeting the needs of the population will lead to service improvements that allows for more equitable, improved and quicker access to care for the patients across the AHSN footprint.</p> <p>The mapping of the lipid service pathway will deliver the following objectives:</p> <ul style="list-style-type: none"> • Collect data along the patient pathway to gather evidence of potential inefficiencies and areas for improvement • Develop an options appraisal for new improved patient pathway throughout Wessex AHSN for patients with lipid disorders • Implement changes to the pathway agreed by the project group • Measure the effect of the implemented changes
Project period	Q4 2022 – Q3 2023

<p>Project objectives</p>	<p>The collaborative working project aims to deliver the following predicted benefits for Patients, the NHS and Sanofi:</p> <p>Patients</p> <ul style="list-style-type: none"> • More equitable and consistent care as well as improved and quicker access to care • Better education around lipid management, better access to treatment options with clearer pathways of care resulting in an improved experience of the system • Potential to reduce health inequalities within this clinical area through consideration of access of specific groups with protected characteristics <p>NHS</p> <ul style="list-style-type: none"> • Better and more efficient patient pathways for Hyperlipidaemia management and/or Familial Hypercholesterolaemia • Support access to relevant diagnostic and screening services for FH • Reduction in the current wait times within the various lipid services across the AHSN footprint • Better identification of patients, more appropriate referrals of patients into pathways/services, more timely assessments with the right Health Care Professionals and treatment options delivered in a timely manner • Better understanding and knowledge of Hyperlipidaemia Management & FH among local HCP's • Increased engagement with appropriate patients to provide additional support and education <p>Sanofi</p> <ul style="list-style-type: none"> • Better understanding of the Hyperlipidaemia and FH services across the Wessex footprint • Greater understanding of the needs of the customer in Hyperlipidaemia and FH • Improved reputation with relevant NHS organisations across the Wessex AHSN area • As Sanofi produces medicines within this disease area if overall patient care is optimised there may be an increase in the usage of these products in line with National and local guidelines. However the focus of the project is
----------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	<p>looking at how the patient flows through the pathway and accesses appropriate services</p>
<p>Contact details</p>	<p>Sanofi Fleur Chandler Head of Market Access UK & IE Sanofi Aventis 410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT. GB-patientaccess@sanofi.com</p> <p>Wessex AHSN Nicola Bent Deputy Chief Executive and Director of Innovation Adoption Innovation Centre, Southampton Science Park, 2 Venture Road, Chilworth, Hampshire, SO16 7NP</p>